AstraZeneca PLC (AZN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol AZN
- Company AstraZeneca PLC
- Price $186.1
- Changes Percentage -1.23
- Change -2.31
- Day Low $185.69
- Day High $190.72
- Year High $195
- Year Low $93.03
- Market Cap $577,015,487,435
- Price Avg 50 EMA (D) $183.58
- Price Avg 200 EMA (D) $159.74
- Exchange NASDAQ
- Volume 1,524,459
- Average Volume 53,472
- Open $187.59
- Previous Close $188.41
- EPS 3.01
- PE 61.83
- Earnings Announcement 2026-02-10 13:30:00
- Shares Outstanding $3,100,566,832
Company brief: ASTRAZENECA PLC (AZN )
- Healthcare
- Drug Manufacturers - General
- Mr. Pascal Soriot D.V.M., M.B.A.
- https://www.astrazeneca.com
- GB
- N/A
- 05-12-1993
- US0463531089
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZN Corporation News
AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA
wsj.com -- The company is working with the U.S. regulator to move forward with an updated application, adding a decision is expected in the first half of 2026....
US FDA rejects AstraZeneca's easier-to-use version of lupus therapy
reuters.com -- AstraZeneca said on Tuesday that the U.S. health regulator had rejected its application for an easier-to-use version of lupus therapy Saphnelo, pushing back the timeline for a possible approval to the...
AstraZeneca begins trading on the New York Stock Exchange
businesswire.com -- WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today begins trading its ordinary shares on the New York Stock Exchange (NYSE) for the first time, enabling more US investors to participate in the Compa...
AstraZeneca begins trading directly on the NYSE
proactiveinvestors.co.uk -- AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares start trading directly on the New York Stock Exchange today, establishing a harmonised global listing along with London and Stockholm. Up to now, US inves...
AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation
cnbc.com -- AstraZeneca has announced it's investing $15 billions in China, and said it is partnering with a Chinese biotech to develop weight-loss drugs. The developments come at a critical time for the pharma i...
AstraZeneca obesity tie-up with CSPC seen as shrewd move
proactiveinvestors.co.uk -- AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) licensing deal on Friday signals a plausible effort by the FTSE 100 group to grab a piece of a booming market for obesity treatments, analysts said, with still...
AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC
wsj.com -- The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars....
AstraZeneca strikes $1.2bn obesity drug deal with China's CSPC
proactiveinvestors.co.uk -- AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) is paying $1.2 billion up-front to seal a tie-up with a Chinese pharma giant aimed at expanding its weight-loss drug pipeline, as it looks to compete in a fast-g...